Zheng Quan Zhi Xing·2025-05-27 14:18Group 1 - The company has signed a new consulting agreement with Dr. Xiaodong Wang, which is a continuation of the previous agreement, effective from May 27, 2025, for a period of three years [1][2] - Under the new agreement, Dr. Wang will receive an annual fixed consulting fee of $100,000, with the possibility of additional discretionary compensation, including a potential bonus of $150,000 [1][2] - The consulting services provided by Dr. Wang will include scientific knowledge and proprietary technology consulting, facilitating communication with academic and investment communities, assisting in recruitment, and promoting business development with other pharmaceutical and biotech companies [1][2] Group 2 - Dr. Wang has significant experience in the pharmaceutical and biotechnology industry, which is expected to contribute positively to the company's development and strategic goals [2] - The continuation of the consulting relationship with Dr. Wang is aligned with the company's strategic and sustainable development needs, benefiting both the company and its shareholders [2]